Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.

@article{Mller2011CosteffectivenessON,
  title={Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.},
  author={J{\"o}rgen M{\"o}ller and Lars Nicklasson and Ananthram Murthy},
  journal={Journal of medical economics},
  year={2011},
  volume={14 6},
  pages={690-7}
}
OBJECTIVE To estimate the cost-effectiveness (cost per additional life-year [LY] and quality-adjusted life-year [QALY] gained) of lenalidomide plus dexamethasone (LEN/DEX) compared with bortezomib for the treatment of relapsed-refractory multiple myeloma (rrMM) in Norway. METHODS A discrete-event simulation model was developed to predict patients? disease… CONTINUE READING